Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Tarenflurbil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 1/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | FABP2 | P12104 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarenflurbil SCHEMBL26131 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL3519037 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL9877586 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | PARKER DANE K (US) | 2026-02-10 | — | — | US | claimed |
| CN-120040283-A | Flurbiprofen axetil salt and preparation method and application thereof | 广东莱恩医药研究院有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2023004482-A1 | AGROCHEMICAL COMBINATION, APPLICATION METHOD AND USE THEREOF | DVA AGRO GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | KYOTO UNIVERSITY (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-3966315-A1 | METHODS FOR THE PRODUCTION OF HEPATOCYTES | FUJIFILM Cellular Dynamics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114144514-A | Method for producing hepatocytes | 富士胶片细胞动力公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3960165-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Fondation EspeRare (CH) | 2022-03-02 | — | — | EP | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| US-20220033780-A1 | METHOD FOR PREPARING INTESTINAL ORGANOID DERIVED FROM PLURIPOTENT STEM CELL | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2022-02-03 | — | — | US | disclosed |
| WO-2022020756-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | MANSELL JOHN (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | PSEN1 568/4885PSEN2 820/4885APH1B 625/4885 |
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | PSEN1 4095/4885PSEN2 3871/4885APH1B 2625/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PSEN1 4607/4885PSEN2 4019/4885APH1B 3278/4885 |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | PAX2, ZP1, ALDH1A2 | PSEN1 137/4885PSEN2 295/4885APH1B 325/4885 |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | NOTCH1, NOTCH4, NOTCH3 | PSEN1 144/4885PSEN2 402/4885APH1B 10/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | PSEN1 1343/4885PSEN2 1969/4885APH1B 2225/4885 |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ALOX15, SOD1, ALOX12 | PSEN1 2798/4885PSEN2 3491/4885APH1B 4563/4885 |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | PSEN1 655/4885PSEN2 895/4885APH1B 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.